Current Problems in Cancer
Volume 33, Issue 1 , Pages 7-64 , January 2009

Multiple Myeloma

References 

  1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860–1873
  2. Rajkumar SV, Kyle RA. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2005;80:1371–1382
  3. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis of monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–569
  4. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362–1369
  5. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ. Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades. Cancer. 2004;101:2667–2674
  6. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  7. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc. 2003;78:21–33
  8. Solly S. Remarks on the pathology of mollities ossium with cases. Medica-Chirurgical Transactions of London. 1844;27:435–461
  9. Macintyre W. Case of mollities and fragilitas ossium, accompanied with urine strongly charged with animal matter. Medica-Chirurgical Transactions of London. 1850;33:211–232
  10. Clamp JR. Some aspects of the first recorded case of multiple myeloma. Lancet. 1967;2:1354–1356
  11. Bence Jones H. Chemical pathology. Lancet. 1847;2:88–92
  12. Bence Jones H. On the new substance occurring in the urine of a patient with mollities ossium. Philos Trans R Soc Land. 1848;138:55–62
  13. Waldeyer W. Ueber bindegewebszellen. Archiv fur Microbiologie and Anatomie. 1875;11:176–194
  14. Wright JH. A case of multiple myeloma. Trans Assoc Am Phys. 1900;15:137–147
  15. Geschickter CF, Copeland MM. Multiple myeloma. Arch Surg. 1928;16:807–863
  16. Perlzweig WA, Delrue G, Geschicter C. Hyperproteinemia associated with multiple myelomas: report of an unusual case. J Am Med Assoc. 1928;90:755–757
  17. Fleischer R. XXIV. Ueber das Vorkommen des sogenannten Bence Jones' schen Eiweisskorpers im normalen Knochenmark. Arch Pathol Anatom Physiol Klin Med. 1880;80:842–849
  18. Bayne-Jones S, Wilson DW. Immunological reactions of Bence-Jones proteins (II. Differences between Bence-Jones proteins from various sources). Bull Johns Hopkins Hosp. 1922;33:119–125
  19. Korngold L, Lipari R. Multiple-myeloma proteins (III. The antigenic relationship of Bence Jones proteins to normal gamma-globulin and multiple-myeloma serum proteins). Cancer. 1956;9:262–272
  20. Tiselius A. A new apparatus for electrophoretic analysis of colloidal mixtures. Transactions of the Faraday Society. 1937;33:524
  21. Tiselius A, Kabat EA. Electrophoretic study of immune sera and purified antibody preparation. J Exp Med. 1939;69:119–131
  22. Longsworth LG, Shedlovsky T, MacInnes DA. Electrophoretic patterns of normal and pathological human blood, serum, and plasma. J Exp Med. 1939;70:399–413
  23. Grabar P, Williams CA. Methode permettant l'etude conjuguee des proprietes electrophoretiques et immunochimiques d'un melange de proteines; application au serum sanguin. Biochim Biophys Acta. 1953;10:193–194
  24. Wilson AT. Direct immunoelectrophoresis. J Immunol. 1964;92:431–434
  25. Waldenstrom J. Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect. 1960;56:211–231
  26. Kyle RA. Multiple myeloma: an odyssey of discovery. Br J Haematol. 2000;111:1035–1044
  27. Alwall N. Urethane and stilbamidine in multiple myeloma: report on two cases. Lancet. 1947;2:388–389
  28. Holland JR, Hosley H, Scharlau C, Carbone PP, Frei E, Brindley CO, et al. A controlled trial of urethane treatment in multiple myeloma. Blood. 1966;27:328–342
  29. Blokhin N, Larionov L, Perevodchikova N, Chebotareva L, Merkulova N. Clinical experiences with sarcolysin in neoplastic diseases. Ann N Y Acad Sci. 1958;68:1128–1132
  30. Bergsagel DE, Sprague CC, Austin C, Griffith KM. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma (IV. L-Phenylalanine mustard (NSC-8806)). Cancer Chemother Rep. 1962;21:87–99
  31. Salmon SE, Shadduck RK, Schilling A. Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma. Cancer Chemother Rep. 1967;51:179–187
  32. Mass RE. A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. Cancer Chemother Rep. 1962;16:257–259
  33. McIntyre OR, Pajak TF, Kyle RA, Cornwell GG, Leone L. Response rate and survival in myeloma patients receiving prednisone alone. Med Pediatr Oncol. 1985;13:239–243
  34. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, et al. Treatment for multiple myeloma (Combination chemotherapy with different melphalan dose regimens). JAMA. 1969;208:1680–1685
  35. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998;16:3832–3842
  36. Thomas ED, Lochte HL, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957;257:491–496
  37. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2:822–824
  38. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–757
  39. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clinic Proc. 2006;81:693–703
  40. Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia. 2006;20:1130–1137
  41. Bohnhorst J, Rasmussen T, Moen SH, Fløttum M, Knudsen L, Borset M, et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia. 2006;20:1138–1144
  42. Mantovani A, Garlanda C. Inflammation and multiple myeloma: the Toll connection. Leukemia. 2006;20:937–938
  43. Perez-Andres M, Almeida J, Martin-Ayuso M, Moro MJ, Martin-Nuñez G, Galende J, et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia. 2005;19:449–455
  44. Rawstron AC, Fenton JA, Ashcroft J, English A, Jones RA, Richards SJ, et al. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood. 2000;96:3880–3886
  45. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64:1546–1558
  46. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175–187
  47. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20:5611–5622
  48. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002;100:1417–1424
  49. Drach J, Angerler J, Schuster J, Rothermundt C, Thalhammer R, Haas OA, et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood. 1995;86:3915–3921
  50. Fonseca R, Aguayo P, Ahmann GJ, Jalal SM, Rajkumar SV, Kyle RA, et al. Translocations at 14q32 are common in patients with the monoclonal gammopathy of undetermined significance (MGUS) and involve several partner chromosomes. Blood. 1999;94(suppl 1):663a;(A 2943)
  51. Rajkumar SV. MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management. Hematology Am Soc Hematol Educ Program. 2005;340–345
  52. Chng WJ, Van Wier SA, Ahmann GJ, Winkler JM, Jalal SM, Bergsagel PL, et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood. 2005;106:2156–2161
  53. Magrangeas F, Lode L, Wuilleme S, Minvielle S, Avet-Loiseau H. Genetic heterogeneity in multiple myeloma. Leukemia. 2005;19:191–194
  54. Kaufmann H, Ackermann J, Baldia C, Nösslinger T, Wieser R, Seidl S, et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia. 2004;18:1879–1882
  55. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002;8:2210–2216
  56. Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Wellik TE, et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood. 2003;101:1715–1717
  57. Galea HR, Cogne M. GM-CSF and IL-12 production by malignant plasma cells promotes cell-mediated immune responses against monoclonal Ig determinants in a light chain myeloma model. Clin Exp Immunol. 2002;129:247–253
  58. Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Di Raimondo F, et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica. 2003;88:176–185
  59. Roodman GD. Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res. 2002;17:1921–1925
  60. Roodman GD. Mechanisms of bone metastasis. [see comment] N Engl J Med. 2004;350:1655–1664
  61. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. [see comment] N Engl J Med. 2003;349:2483–2494
  62. Katzmann JA, Dispenzieri A, Kyle R, Snyder MR, Plevak MF, Larson DR, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc. 2006;81:1575–1578
  63. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;134:573–589
  64. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437–1444
  65. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet. 2003;361:489–491
  66. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97:2900–2902
  67. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122:78–84
  68. Abraham RS, Clark RJ, Bryant SC, Lymp JF, Larson T, Kyle RA, et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem. 2002;48:655–657
  69. Durie BG, Salmon SE. A clinical staging system for multiple myeloma (Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival). Cancer. 1975;36:842–854
  70. Kyle RA. Prognostic factors in multiple myeloma. Stem Cells. 1995;2:56–63
  71. Rapoport BL, Falkson HC, Falkson G. Prognostic factors affecting the survival of patients with multiple myeloma (A retrospective analysis of 86 patients). S Afr Med J. 1990;79:65–67
  72. Greipp PR, San Miguel JF, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–3420
  73. Rajkumar SV, Greipp PR. Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am. 1999;13:1295–1314
  74. Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S, et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol. 1997;15:2659–2666
  75. Greipp PR. Prognosis in myeloma. [Review] Mayo Clin Proc. 1994;69:895–902
  76. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001;97:1566–1571
  77. Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA, et al. Plasmablastic morphology–an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998;91:2501–2507
  78. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. [see comments] Blood. 1993;81:3382–3387
  79. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, et al. Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): Consensus Statement. Mayo Clin Proc. 2007;82:323–341
  80. Blade J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation (Myeloma Subcommittee of the EBMT (European Group for Blood and Marrow Transplant)). Br J Haematol. 1998;102:1115–1123
  81. Durie BGM, Harousseau J-L, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473
  82. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddiemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. [see comments] N Engl J Med. 1999;341:1565–1571
  83. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–2617
  84. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. [see comment] N Engl J Med. 2005;352:2487–2498
  85. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005;106:4050–4053
  86. Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108:3458–3464
  87. Lenz W. A short history of thalidomide embryopathy. Teratology. 1988;38:203–215
  88. Lenz W. A personal perspective on the thalidomide tragedy. Teratology. 1992;46:417–418
  89. Stephens T, Brynner R. Dark Remedy (The Impact of Thalidomide and Its Revival As a Vital Medicine). Cambridge, MA: Perseus Publishing; 2001;
  90. Lenz W. Thalidomide and congenital abnormalities. Lancet. 1962;1:45
  91. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961;2:1358
  92. Geraghty K. Profile of a role model: Francis Oldham Kelsey, MD, PhD. Vol. 2003 (ed http://www.ama-assn.org/ama/pub/printcat/5335.html): American Medical Association, 2001.
  93. Rogerson G. Thalidomide and congenital abnormalities. Lancet. 1962;1:691
  94. Woodyatt PB. Thalidomide. Lancet. 1962;1:750
  95. Grabstad H, Golbey R. Clinical experience with thalidomide in patients with cancer. Clin Pharmacol Therap. 1965;6:298–302
  96. Olson KB, Hall TC, Horton J, Khung CL, Hosley HF. Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer. Clin Pharmacol Ther. 1965;6:292–297
  97. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther. 1965;6:303–306
  98. Iyer CG, Languillon J, Ramanujam K, Tarabini-Castellani G, De las Aguas JT, et al. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ. 1971;45:719–732
  99. Mascaro JM, Lecha M, Torras H. Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis. Arch Dermatol. 1979;115:636–637
  100. Lim SH, McWhannell A, Vora AJ, Boughton BJ. Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation. Lancet. 1988;1:117
  101. Saurat JH, Camenzind M, Helg C, Chapuis B. Thalidomide for graft-versus-host disease after bone marrow transplantation. Lancet. 1988;1:359
  102. Vogelsang GB, Santos GW, Colvin OM, Chen T. Thalidomide for graft-versus-host disease. Lancet. 1988;1:827
  103. Vogelsang GB, Wells MC, Santos GW, Chen TL, Hess AD. Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model. Transplant Proc. 1988;20:226–228
  104. Ringden O, Aschan J, Westerberg L. Thalidomide for severe acute graft-versus-host disease. Lancet. 1988;2:568
  105. Youle M, Clarbour J, Farthing C, Connolly M, Hawkins D, Slaughton R, et al. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. BMJ. 1989;298:432
  106. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, Arroyo-Figueroa H, Pasquetti A, Calva JJ, et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. Aids. 1996;10:1501–1507
  107. Zeldis JB, Williams BA, Thomas SD, Elsayed ME. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther. 1999;21:319–330
  108. Lary JM, Daniel KL, Erickson JD, Roberts HE, Moore CA. The return of thalidomide: can birth defects be prevented?. Drug Saf. 1999;21:161–169
  109. Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol. 2001;57:365–376
  110. Stirling DI. Pharmacology of thalidomide. Semin Hematol. 2000;37:5–14
  111. Eriksson T, Bjorkman S, Roth B, Fyge A, Hoglund P. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality. 1995;7:44–52
  112. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082–4085
  113. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 1997;64:971–978
  114. Barlogie B, Spencer T, Tricot G, Zeldis J, Munshi N, Zangari M, et al. Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). Blood. 2000;96:514a;(A2213)
  115. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc. 2000;75:897–902
  116. Kumar S, Gertz MA, Dispenzieri A, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. [comment] Mayo Clin Proc. 2003;78:34–39
  117. Rajkumar SV, Witzig TE. A review of angiogenesis and anti-angiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev. 2000;26:351–362
  118. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319–4323
  119. Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MQ, Geyer S, Lust JA, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001;15:1274–1276
  120. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003;17:775–779
  121. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16–19
  122. Rajkumar SV, Gertz MA, Kyle RA, Greipp PR. Current therapy for multiple myeloma. Mayo Clin Proc. 2002;77:813–822
  123. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol. 2003;121:768–771
  124. Dimopoulos MA, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J. 2004;5:112–117
  125. Garcia-Sanz R, Gonzalez-Fraile MI, Sierra M, Lopez C, Gonzalez M, San Miguel JF. The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma. Hematol J. 2002;3:43–48
  126. Kropff MH, Lang N, Bisping G, Dominé N, Innig G, Hentrich M, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol. 2003;122:607–616
  127. Coleman M, Leonard J, Lyons L, Pekle K, Nahum K, Pearse R, et al. BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia. Leuk Lymphoma. 2002;43:1777–1782
  128. Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol. 2003;1:194–205
  129. Osman K, Comenzo R, Rajkumar SV. Deep vein thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med. 2001;344:1951–1952
  130. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614–1615
  131. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifer F, Fassas A, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002;100:1168–1171
  132. Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 2002;13:187–192
  133. Rajkumar SV, Gertz MA, Witzig TE. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med. 2000;343:972–973
  134. Badros AZ, Siegel E, Bodenner D, Zangari M, Zeldis J, Barlogie B, et al. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med. 2002;112:412–413
  135. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492–494
  136. Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol. 2003;21:4444–4454
  137. Adams J. Development of the proteasome inhibitor PS-341. Oncologist. 2002;7:9–16
  138. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol. 2001;28:613–619
  139. Adams J. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol. 2002;14:628–634
  140. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 1994;79:13–21
  141. Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs. 2000;18:109–121
  142. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Op Chem Biol. 2002;6:493–500
  143. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425–479
  144. Varshavsky A. The ubiquitin system. Trend Biochem Sci. 1997;22:383–387
  145. Craiu A, Gaczynska M, Akopian T, Gramm CF, Fenteany G, Goldberg AL, et al. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem. 1997;272:13437–13445
  146. Orlowski M. The multicatalytic proteinase complex, a major extralysosomal proteolytic system. Biochemistry. 1990;29:10289–10297
  147. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 1996;65:801–847
  148. Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia. 2002;16:433–443
  149. Braun BC, Glickman M, Kraft R, Dahlmann B, Kloetzel PM, Finley D, et al. The base of the proteasome regulatory particle exhibits chaperone-like activity. Nat Cell Biol. 1999;1:221–226
  150. Kloetzel PM. Antigen processing by the proteasome. Nat Rev Mol Cell Biol. 2001;2:179–187
  151. Pickart CM, VanDemark AP. Opening doors into the proteasome. [comment] Nat Struct Biol. 2000;7:999–1001
  152. Groll M, Bajorek M, Kohler A, Moroder L, Rubin DM, Huber R, et al. A gated channel into the proteasome core particle. [comment] Nature Struct Biol. 2000;7:1062–1067
  153. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. [comment] Science. 1995;268:533–539
  154. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615–2622
  155. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 1998;58:4342–4348
  156. Drexler HC. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A. 1997;94:855–860
  157. Delic J, Masdehors P, Omura S, Cosset JM, Dumont J, Binet JL, et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. [comment] Br J Cancer. 1998;77:1103–1107
  158. An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Diff. 1998;5:1062–1075
  159. Traenckner EB, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J. 1994;13:5433–5441
  160. Mori S, Tanaka K, Omura S, Saito Y. Degradation process of ligand-stimulated platelet-derived growth factor beta-receptor involves ubiquitin-proteasome proteolytic pathway. J Biol Chem. 1995;270:29447–29452
  161. Cusack JC, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001;61:3535–3540
  162. Russo SM, Tepper JE, Baldwin AS, Liu R, Adams J, Elliott P, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Rad Oncol Biol Phys. 2001;50:183–193
  163. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem. 2001;82:110–122
  164. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999;5:2638–2645
  165. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res. 2000;6:3719–3728
  166. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res. 2001;100:11–17
  167. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071–3076
  168. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gus X, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002;99:14374–14379
  169. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377–2380
  170. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62:4996–5000
  171. Berenson JR, Jagannath S, Barlogie B, Siegel D, Alexanian R, Irwin D, et al. Experience with long-term therapy using the proteasome inhibitor, bortezomib, in advanced multiple myeloma (MM). Proc Am Soc Clin Oncol. 2003;22:581
  172. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063–3067
  173. Zangari M, Tricot G, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B. Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT). Blood. 2001;775a;(A3226)
  174. Dimopoulos MA, Spencer A, Attal M, Prince M, Harousseau J-L, Dmoszynska A, et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010). Blood. 2005;106:6
  175. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer E, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009). Proc Am Soc Clin Oncol. 2006;24:A7521
  176. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892–3901
  177. Streetly M, Jones RW, Knight R, Rassam S, Gillett D, Singer C, et al. An update of the use and outcomes of the new immunomodulatory agent CC-4047 (Actimid) in patients with relapsed/refractory myeloma. Blood. 2003;102:236a
  178. Lacy MQ, Hayman SR, Gertz MA, Alfred JB, Mandrekar SJ, Dispenzieri A, et al. Pomalidomide (CC4047) plus low-dose dexamethasone (Pom/dex) is highly effective therapy in relapsed multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2008;112:866
  179. Jagannath S, Vij R, Stewart AK, Somlo G, Jakubowiak A, Reiman T, et al. Initial results of PX-171-003, an open-label, single-arm, phase iI study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts). 2008;112:864
  180. Vij R, Wang M, Orlowski R, Stewart AK, Jagannath S, Kukreti V, et al. Initial results of PX-171-004, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed myeloma (MM). Blood (ASH Annual Meeting Abstracts). 2008;112:865
  181. Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol. 2001;28:607–612
  182. Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer. 2008;113:1588–1595
  183. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106:35–39
  184. Fermand J-P, Jaccard A, Macro M, Uzunhan Y, Allard C, Castaigne S, et al. A Randomized comparison of dexamethasone + thalidomide (Dex/Thal) vs Dex + placebo (Dex/P) in patients (pts) with relapsing multiple myeloma (MM). Blood. 2006;108:3563
  185. Rajkumar SV, Blood E, Vesole DH, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431–436
  186. Weber DM, Gavino M, Delasalle K, Rankin K, Giralt S, Alexanian R. Thalidomide alone or with dexamethasone for multiple myeloma. Blood. 1999;94(suppl 1):604a;(A 2686)
  187. Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica. 2004;89:826–831
  188. Rajkumar SV, Rosiñol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L, et al. A multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone versus dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008;26:2171–2177
  189. Lokhorst H, van der Holt B, Zweegman S, Von Dem Borne PA, Bos GMJ, Croockewit S, et al. Final Analysis of HOVON-50 randomized phase III study on the effect of thalidomide combined with adriamycine, dexamethasone (AD) and high dose melphalan (HDM) in patients with multiple myeloma (MM). ASH Annual Meeting Abstracts. 2008;112:157
  190. Lacy M, Gertz M, Dispenzieri A, Hayman S, Geyer S, Zeldenrust S, et al. Lenalidomide plus dexamethasone (Rev/Dex) in newly diagnosed myeloma: response to therapy, time to progression, and survival. Blood. 2006;108:798
  191. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Greipp P. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood. 2006;108:799
  192. Richardson PG, Chanan-Khan A, Schlossman RL, Munshi NC, Wen P, Briemberg H, et al. Phase II trial of single agent bortezomib (VELCADE®) in patients with previously untreated multiple myeloma (MM). Blood. 2004;104:100a;(A336)
  193. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzsky J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005;129:776–783
  194. Harousseau J, Attal M, Leleu X, Troney J, Pegourie B, Stoppa A, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006;91:1498–1505
  195. Harousseau J-L, Marit G, Caillot D, Casassus P, Facon T, Mohty M, et al. VELCADE/dexamethasone (Vel/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): an interim analysis of the IFM 2005-01 randomized multicenter phase III trial. Blood. 2006;108:56
  196. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138:176–185
  197. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825–831
  198. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Renaud M, et al. Major superiority of melphalan - prednisone (MP) + Thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood. 2005;106:230a;(A780)
  199. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209–1218
  200. Hulin C, Virion J, Leleu X, Rodon P, Pegourie B, Benboubker L, et al. Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM) (Preliminary results of the randomized, double-blind, placebo controlled IFM 01-01 trial). J Clin Oncol (Meeting Abstracts). 2007;25:8001
  201. Wijermans P, Schaafsma M, van Norden Y, Ammerlaan R, Wittebol S, Sinnige H, et al. Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch Cooperative Group HOVON 49 Study. Blood (ASH Annual Meeting Abstracts). 2008;112:649
  202. Waage A, Gimsing P, Juliusson G, Turesson I, Fayers P. Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial. ASH Annual Meeting Abstracts. 2007;110:78
  203. Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008;112:3107–3114
  204. San Miguel JF, Schlag R, Khuageva NK, Dimopoulis MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–917
  205. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA Italian Multiple Myeloma Network. J Clin Oncol. 2007;25:4459–4465
  206. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma (Intergroupe Francais du Myelome). N Engl J Med. 1996;335:91–97
  207. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–1883
  208. Blade J, Vesole DH, Gertz M. Transplantation for multiple myeloma: who, when, how often?. Blood. 2003;102:3469–3477
  209. Kumar A, Loughran T, Alsina M, Durie BG, Djulbegovic B. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol. 2003;4:293–304
  210. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood. 2002;99:731–735
  211. Bensinger W, Giralt S, Holmberg L, Eary J, Goodman M, Podoloff D, et al. 166H0-DOTMP and high-dose melphalan before autologous peripheral blood stem cell transplantation in patients with multiple myeloma. Hematol J. 2003;4(suppl 1):S215–S216
  212. Dispenzieri A, Wiseman GA, Lacy MQ, Geyer S, Litzow MR, Tefferi A, et al. A phase II study of high dose 153-samarium EDTMP (153-Sm EDMTP) and melphalan for peripheral stem cell transplantation (PBSCT) in multiple myeloma (MM). Blood. 2003;102:982a
  213. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Berlanger C, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? (Results of a multicenter sequential randomized clinical trial). Blood. 1998;92:3131–3136
  214. Facon T, Mary JY, Harousseau JL, Attal M, Bosly A, Michaux JL, et al. Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM) (Preliminary results of a prospective randomized trial (CIAM) protocol). Blood. 1996;88(suppl 1):685a
  215. Barlogie B, Kyle R, Anderson K, Greipp P, Lazarus H, Jacobson J, et al. Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing MEL 140 mg/m2 + TBI 12 Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: results of Intergroup Trial S9321. Blood. 2003;102:42a
  216. Blade J, Sureda A, Ribera JM, Diaz-Mediavilla J, Garca-Laraa J, et al. High-dose therapy autotransplantation/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy (Definitive results from PETHEMA after a median follow-up of 66 months). Blood. 2003;102:42a
  217. Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, et al. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant. 1999;23:1267–1272
  218. Blade J, Esteve J. Treatment approaches for relapsing and refractory multiple myeloma. [Review] Acta Oncol. 2000;39:843–847
  219. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789–793
  220. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55–65
  221. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Double Autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the “Intergroupe Francophone du Myelome” (IFM 94). Blood. 2002;100:5a
  222. Cavo M, Cellini C, Zamagni E, Tosi P, Cangini D, Tacchetti P, et al. Superiority of double over single autologous stem cell transplantation as first-line therapy for multiple myeloma. Blood. 2004;104:155a;(A536)
  223. Fermand JP, Alberti C, Marolleau JP. Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34-enriched ABSC: results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM). Hematol J. 2003;4(suppl 1):S59
  224. Goldschmidt H. Single vs. tandem autolgous transplantation in multiple myeloma: the GMMG experience. Hematol J. 2003;4(suppl 1):S61
  225. Sirohi B, Powles R, Singhal S, Treleaven J, Kulkarni S, Horton C, et al. High-dose melphalan and second autografts for myeloma relapsing after one autograft: results equivalent to tandem autotransplantation. Blood. 2001;98:402a;(A1690)
  226. Mehta J, Singhal S. Graft-versus-myeloma. Bone Marrow Transplant. 1998;22:835–843
  227. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Björkstrand B, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001;113:209–216
  228. Einsele H, Schafer HJ, Hebart H, Bader P, Meisner C, Plasswilm L, et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol. 2003;121:411–418
  229. Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, MacKinnon S, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood. 2005;105:4532–4539
  230. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102:3447–3454
  231. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoab-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107:3474–3480
  232. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Sehianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356:1110–1120
  233. Rosinol L, Perez-Simon JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112:3591–3593
  234. Mateos M-V, Hernandez J-M, Hernandez M-T, Gutiérrez NC, Palomera L, Fuertes M, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006;108:2165–2172
  235. Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2006;21:151–157
  236. Sagaster V, Ludwig H, Kaufmann H, Odelga V, Zojer N, Ackermann J, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia. 2006;21:164–168
  237. Myeloma Trialists' Collaborative G. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol. 2001;113:1020–1034
  238. Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002;99:3163–3168
  239. Attal M, Harousseau J-L, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108:3289–3294
  240. Spencer A, Prince M, Roberts AW, Bradstock KF, Prosser IW. First Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) trial of thalidomide and alternate day prednisolone following autologous stem cell transplantation (ASCT) for patients with multiple myeloma (ALLG MM6). ASH Annual Meeting Abstracts. 2006;108:58
  241. Offidani M, Polloni C, Corvatta L, Piersantelli M-N, Galieni P, Visani G, et al. Thalidomide-dexamethasone vs interferon-{alpha}-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma (MM): final analysis of a prospective, randomized study. ASH Annual Meeting Abstracts. 2007;110:532
  242. Abdelkefi A, Ladeb S, Torjman L, Othman TB, Lakhal A, Romdhane NB, et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood. 2008;111:1805–1810
  243. Maiolino A, Hungria VT, Oliveira-Duarte G, Oliviera LC, Mercante DR, Miranda Ecm, et al. Thalidomide + dexamethasone as maintenance after single autologous stem cell transplantation improves progression-free survival (PFS) in advanced multiple myeloma (A Prospective Brazilian Randomized Trial). ASH Annual Meeting Abstracts. 2008;112:3703
  244. Morgan GJ, Jackson GH, Davies FE, Drayson MT, Owen RG, Gregory WM, et al. Maintenance thalidomide may improve progression free but not overall survival; results from the Myeloma IX Maintenance Randomisation. Blood (ASH Annual Meeting Abstracts). 2008;112:656
  245. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. [see comment] N Engl J Med. 2006;354:1021–1030
  246. Gertz MA, Lacy MQ, Inwards DJ, Chen MG, Pineda AA, Gastineu DA, et al. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Bone Marrow Transplant. 1999;23:221–226
  247. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med. 1986;105:8–11
  248. Gertz MA, Garton JP, Greipp PR, Witzig TE, Kyle RA. A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia. 1995;9:2115–2118
  249. Gucalp R, Theriault R, Gill I, Madajewicz S, Chapman R, Navari R, et al. Treatment of cancer-associated hypercalcemia (Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone). Arch Intern Med. 1994;154:1935–1944
  250. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19:558–567
  251. Berenson JR, Lichtenstein A, Porter L, Dimopoulis MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma (Myeloma Aredia Study Group). [see comments] N Engl J Med. 1996;334:488–493
  252. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. [Published erratum in Cancer 2001;91(10):1956] Cancer. 2001;91:1191–1200
  253. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastatses in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase II, double blind, comparative trial. Cancer J. 2001;7:377–387
  254. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, et al. American Society of Clinical Oncology Clinical Practice Guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20:3719–3736
  255. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. [see comment] J Oral Maxillofac Surg. 2003;61:1115–1117
  256. Kademani D, Koka S, Lacy MQ, Rajkumar SV. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc. 2006;81:1100–1103
  257. Badros A, Weikel D, Salama A, Goloubera O, Schneider A, Rappoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006;24:945–952
  258. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99–102
  259. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527–534
  260. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81:1047–1053
  261. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulis I, Gika D, Moulopoulos LA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91:968–971
  262. Melton LJ, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res. 2005;20:487–493
  263. Fourney DR, Schomer DF, Nader R, Chlan-Fourney J, Suki D, Ahrar K, et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg. 2003;98:21–30
  264. Yussim E, Schwartz E, Sidi Y, Ehrenfeld M. Acute renal failure precipitated by non-steroidal anti-inflammatory drugs (NSAIDs) in multiple myeloma. Am J Hematol. 1998;58:142–144
  265. Wu MJ, Kumar KS, Kulkarni G, Kaiser H. Multiple myeloma in naproxen-induced acute renal failure. N Engl J Med. 1987;317:170–171
  266. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma (Plasmapheresis, hemodialysis, and chemotherapy). Arch Intern Med. 1990;150:863–869
  267. Garton JP, Gertz MA, Witzig TE, Greipp PR, Lust JA, Schroeder G, et al. Epoetin alfa for the treatment of the anemia of multiple myeloma (A prospective, randomized, placebo-controlled, double-blind trial). Arch Intern Med. 1995;155:2069–2074
  268. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. [Published erratum in Br J Haematol 2001;114(3):738] Br J Haematol. 2001;113:172–179
  269. Oken MM, Pomeroy C, Weisdorf D, Bennett JM. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med. 1996;100:624–628
  270. Gertz MA, Kyle RA. Hyperviscosity syndrome. J Intensive Care Med. 1995;10:128–141
  271. Rajkumar SV, Kyle RA. Multiple myeloma: diagnosis and treatment. [see comment] Mayo Clin Proc. 2005;80:1371–1382
  272. Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003;102:3759–3764
  273. Gobbi PG, Baldini L, Broglia C, Goldaniga M, Comelli M, Morel P, et al. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?. Clin Cancer Res. 2005;11:1786–1790
  274. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Semin Oncol. 2003;30:169–171
  275. Baldini L, Goldaniga M, Guffanti A, Broglia C, Cortelazzo S, Rossi A, et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol. 2005;23:4662–4668
  276. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30:110–115
  277. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000;96:2037–2044
  278. Dimopoulos MA, Kiamouris C, Moulopoulos LA. Solitary plasmacytoma of bone and extramedullary plasmacytoma. Hematol Oncol Clin North Am. 1999;13:1249–1257
  279. Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR, et al. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101:2496–2506
  280. Browman GP, Bergsagel D, Sicheri D, Or S, Wilson KS, Rubin S, et al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1995;13:2354–2360
  281. Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol. 2002;118:1041–1047
  282. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24:929–936
  283. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. [see comment] N Engl J Med. 2003;349:2495–2502
  284. Blade J, Rosinol L, Sureda A, Ribera JM, Diaz-Mediavilla J, Garcia-Larana J, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood. 2005;106:3755–3759
  285. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M, et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial Coordinated by the Eastern Cooperative Oncology Group. ASH Annual Meeting Abstracts. 2007;110:74
  286. Harousseau JL, Mathiot C, Attal M, Marit G, Caillot D, Mohty MMM, et al. VELCADE/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantion (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 Trial. ASH Annual Meeting Abstracts. 2007;110:450
  287. Cavo M, Patriarca F, Tacchetti P, Galli M, Perrone G, Petrucci MT, et al. Bortezomib (velcade(R))-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). ASH Annual Meeting Abstracts. 2007;110:73
  288. Harousseau JL, Attal M. The role of stem cell transplantation in multiple myeloma. Blood Rev. 2002;16:245–253
  289. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23:9227–9233
  290. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004;104:3052–3057
  291. Sonneveld P, van der Holt B, Vellenga E, Croockewit S, Verhoef G, Segeren C, et al. Intensive versus double intensive therapy in untreated multiple myeloma: final analysis of the HOVON 24 Trial. ASH Annual Meeting Abstracts. 2005;106:2545

PII: S0147-0272(09)00002-6

doi: 10.1016/j.currproblcancer.2009.01.001

Current Problems in Cancer
Volume 33, Issue 1 , Pages 7-64 , January 2009

Article Tools

* Image Usage & Resolution